000 03189nam a22004095c 4500
999 _c6737
_d6737
001 6737
003 ES-MaUEC
005 20200630101704.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 181127s2019 gw a s |||| 0|eng d
020 _a9783319935300
024 7 _a10.1007/978-3-319-93530-0
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC270
_b.I46 2019EB
245 0 0 _aImmunotherapy of Sarcoma
_cedited by Sandra P. D'Angelo, Seth M. Pollack.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Springer
_c2019.
300 _aVII, 152 páginas 10 ilustraciones, 7 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 0 _aMedicine (Springer-11650)
505 0 _aPart 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.
520 3 _aThis book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.
650 1 4 _aOncology.
_0http://scigraph.springernature.com/things/product-market-codes/H33160
653 0 _aOncology  .
653 0 _aImmunology.
700 1 _aD'Angelo, Sandra P.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aPollack, Seth M.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783319935294
776 0 8 _iPrinted edition:
_z9783319935317
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-93530-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_el